Another study assessing response of NSCLC to immunotherapy, 103 patients treated with anti-PD-L1 agent (atezolizumab) were evaluated the potential of FDG PET-CT for assessing response [30]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.